ArticleJPGN reports2022
Relapse of Eosinophilic Esophagitis on Dupilumab.
Article in JPGN reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- The Therapeutic Pipeline for Eosinophilic Esophagitis: Current Landscape and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A nationwide experience of biological treatments in children with eosinophilic esophagitis.Pediatric research · 2025Article
- Eosinophilic esophagitis: Current concepts in diagnosis and management.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Dupilumab is approved for the treatment of eosinophilic esophagitis (EoE). We report a teenager with difficult-to-treat EoE on topical corticosteroids (TS) who achieved clinical and histological remission when initiated on dupilumab for a primary indication of atopic dermatitis. However, when his TS were weaned after achieving remission, his disease relapsed with worsening of his dysphagia and a peak eosinophilic count (PEC) of 55 eosinophils per high power field (eos/hpf). Upon restarting TS to his ongoing dupilumab, symptoms fully resolved, and he achieved histologic remission (PEC 10 eos/hpf). This report underscores the: (1) importance of longitudinal monitoring for EoE patients on dupilumab, (2) unmet need for guidance on how to transition EoE patients on traditional therapies to dupilumab, and (3) need for longitudinal follow-up data on dupilumab to help personalize therapy for EoE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.